Navigation Links
New Pre-Clinical and Clinical Data on GeNO LLC's Nitric Oxide Delivery Systems to Be Presented at 2013 American College of Cardiology and American Thoracic Society Medical Meetings
Date:1/29/2013

ry cartridge technology. These experiments demonstrate that nitric oxide derived from liquid N2O4 is equally efficacious as nitric oxide derived from NO2 gas in lowering mean pulmonary arterial pressure (mPAP) and PVR in a mammal.  The amount of nitric oxide generated with 0.2 ml of N2O4 is enough to deliver nitric oxide for >24 hours at flow rates used for nasal cannula delivery systems. 

"A Phase 2 Open Label Pilot Study Evaluating Preliminary Safety and Performance of the GeNO Nitrosyl Delivery System" will be presented at the American Thoracic Society International Conference in Philadelphia, PA on May 20, 2013.  This is the first clinical study to demonstrate that inhaled nitric oxide can be delivered in adult pulmonary arterial hypertension (PAH) patients with GeNO's inhaled nitric oxide delivery system in combination with approved PAH therapies with expected selective acute pulmonary hemodynamic effects.

"The data to be presented at these meetings provide important new insights into the clinical utility of ultrapure, inhaled nitric oxide delivered by GeNO's nitric oxide delivery system," said Dr. David Fine , Chief Executive Officer, GeNO LLC .

Dr. Robert Roscigno , Executive Vice President of Clinical Development, GeNO LLC, stressed that "as we advance this investigational product into late stage clinical trials for various forms of Pulmonary Hypertension, additional therapeutic options are still needed.  These data support further clinical development of GeNO's technologies for use by patients in need of acute and chronic Pulmonary Hypertension therapies."

In 2012, GeNO announced that its New Drug Application (NDA) for the GeNOsyl™ MVG-2000 Nitric Oxide Delivery System for neonates with hypoxic respiratory failure had been accepted
'/>"/>

SOURCE GeNO LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Significant Pre-Clinical Data in Acute Lung Injury
2. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
3. MicroConstants China Signs Site Management Organization Agreement with the Clinical Research Center of No. 307 Hospital
4. GLP Preclinical Studies Demonstrate nContact Ablation Lesions Are Complete and Transmural
5. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
6. Projecis Demonstrates Flagship Project Management Software at Outsourcing Clinical Trials-West in San Francisco
7. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
8. Hadasit Bio-Holdings Portfolio Companies Receive Funding to Support Clinical Trial Preparations and Obtain Regulatory Approvals in U.S. and Europe
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Diet Doc Weight Loss Diets and Fast Weight Loss Plans To Seek Patent Protection for the Most Clinically Advanced Diet Offered in the United States.
11. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
(Date:9/19/2014)... Kiromic, LLC, a Lubbock bio-pharmaceutical company, ... former chancellor of Texas Tech University, to its board as ... after raising $1.2 billion for the university. "Kiromic ... most successful chancellor in the history of Texas Tech University, ... but also as our new vice chairman of the board. ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014  For ... cloud-based drug design and development, partnering is an ... mission is to design new drugs and identify ... 2 partners to further their development. The company ... investments. To support this business model, Cloud Pharmaceuticals ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Data in Pediatric Patients,Presented at the American ... N.J., Nov. 11 Daiichi Sankyo,Inc. (DSI), ... study supporting,the use of colesevelam HCl in ... presented for the first time at the,American ...
... 3.5 Fold Higher ... Compared to Standard Chemotherapy, SEATTLE, Nov. 11 ... it achieved the primary,efficacy endpoint of its phase III EXTEND ... non-Hodgkin,s,lymphoma (NHL) based on a preliminary intent to treat efficacy ...
Cached Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4
(Date:9/21/2014)... cells metastasize? Think of Sparta. , Ancient Greek warriors ... for the demands of battle on distant fields. Cancer ... to a new study revealing previously unknown differences between ... tumor site, and those that travel to other organs. ... metastasize is the primary cause of cancer-related death, understanding ...
(Date:9/21/2014)... 2014 Hundreds of Risperdal lawsuits ... Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard ... next monthly meeting has been scheduled for October ... “Our Firm is representing a number of plaintiffs ... We are pleased with its continued progress,” says ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the ... and GreenGeeks are the best Reseller hosting suppliers in ... hosting supplier. Actually, these companies have outperformed their competitors ... People can get the best web hosting at affordable ... to the manager, reseller hosting is a very popular ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 ... Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a ... and Chinese Fenofibrate (CAS 49562-28-9) industry. The ... Fenofibrate (CAS 49562-28-9) including its classification, application ... and China’s top manufacturers of Fenofibrate (CAS ...
(Date:9/21/2014)... 21, 2014 More than 60 ... added over the past month to a federal ... cardiovascular injuries caused by the dialysis concentrate, Bernstein ... on September 15th shows 2,089 cases filed in ... Court, District of Massachusetts. These claims were filed ...
Breaking Medicine News(10 mins):Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4
... ... sugar and high in antioxidants. Summer is just around the corner so look and feel great ... the healthiest berry on earth! , ... York, NY (PRWEB) April 26, 2010 -- Move over acai, there’s a new berry in town ...
... degrees, for men with advanced disease, studies found, , ... this week of a therapeutic prostate cancer vaccine by ... milestone against the disease and cancer in general, experts ... survival in men with advanced prostate cancer, and it ...
... , ... at the recent 2010 DTC National Conference in Washington, D.C., agreed 2-1 that they would ... , ... Park, NJ (PRWEB) April 27, 2010 -- DTC Perspectives, Inc ., the leading conference, ...
... ... Exclusively at Target, with four all-natural treatment collections for all hair types and ethnicities. ... (PRWEB) April ... Care, which debuted exclusively in 233 Target stores on March 28, 2010. An ...
... ... their own custom branded mobile application to iPhone, iPad, and Android devices without having to ... ... its platform that allows businesses to build and deploy their own mobile application, ...
... ... to take place on May 6, 2010. Two years in the planning and development, ... center offers nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott ...
Cached Medicine News:Health News:Supercharge Summer with Superfood-infused Cookies! 2Health News:Supercharge Summer with Superfood-infused Cookies! 3Health News:Prostate Cancer Vaccine May Get FDA Approval 2Health News:Prostate Cancer Vaccine May Get FDA Approval 3Health News:Top DTC Marketers Choose Obama Over Romney and Palin 2Health News:Top DTC Marketers Choose Obama Over Romney and Palin 3Health News:Sundial Creations Announces the Debut of SheaMoisture Organic Hair Care Exclusively at Target 2Health News:Snowflake Mobile™ Launches Platform for Creating and Deploying Mobile Apps 2Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: